Stage 1 of a phase 2/3 RCT (400 adults, drug-susceptible TB, China): safety-related discontinuation by week 8 was 9.3%, 8.9% and 14.6% with 4-month rifapentine 10, 15 and 20 mg/kg regimens vs 3.0% with the standard 6-month regimen.
RCTn = 400
Li et al. Rifapentine dosing for drug-susceptible tuberculosis: stage 1 of a seamless phase 2/3 randomized clinical trial